



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Paper

Transdermal drug delivery system: A journey through the skin

Pratik Gayke*, Suvarna Bhokare , Abhay Gholwe, Sachin Ghule, Shubham Ghuge, Monika Ghuge

Srinath College Of Pharmacy, Waluj, Bajaj Nagar, Chhatrapati Sambhajinagar, Maharashtra, India- 431136.

ARTICLE INFO

Published: 27 Apr 2026

Keywords:

Transdermal drug delivery ,
journey through the skin,
(TDDS)

DOI:

10.5281/zenodo.19815645

ABSTRACT

The Transdermal Drug Delivery System (TDDS) is a cutting-edge way to deliver medications right through the skin and into the bloodstream. Unlike the traditional methods of swallowing pills or getting injections, this system utilizes patches or other skin-applied forms to release drugs slowly and in a controlled manner. It's becoming increasingly popular because it's easy to use, painless, and enhances patient comfort and adherence to treatment. Plus, it sidesteps the issues often associated with oral medications, like those involving the digestive system and liver. The concept behind TDDS is to transform the skin from just a protective barrier into a pathway for medicine. Our skin consists of several layers, with the outermost layer (the stratum corneum) acting as the primary barrier to drug absorption. For a drug to be effectively delivered, it needs to be formulated in a way that allows it to penetrate these layers without causing harm to the skin. Various techniques, including penetration enhancers, microneedles, iontophoresis, and specialized chemical formulations, have been developed to facilitate this process. This report delves into the structure of the skin, how transdermal systems work, the types of drugs that are suitable for this delivery method, and the evolution of transdermal technologies. It also highlights the advantages, such as maintaining consistent drug levels in the bloodstream, minimizing side effects, and enhancing safety. However, TDDS does have its drawbacks—some drugs simply aren't suitable for skin delivery, and certain individuals may experience skin irritation. There are already a variety of transdermal patches on the market for issues like pain relief, birth control, hormone replacement, and helping people quit smoking. With ongoing research, we're seeing the development of even more innovative systems that can deliver a broader range of medications. In summary, the Transdermal Drug Delivery System represents a powerful and patient-friendly approach to modern medicine. As we continue to learn more about skin science and drug formulation, TDDS is poised to become even more effective and widely adopted in the future. This report will guide you through this fascinating journey.

***Corresponding Author:** Pratik Gayke

Address: Srinath College Of Pharmacy, Waluj, Bajaj Nagar, Chhatrapati Sambhajinagar, Maharashtra, India- 431136

Email ✉: pratikgayke2@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



INTRODUCTION

In today's world, where medical science is growing rapidly, the way we take medicines is also changing. Traditional methods like swallowing tablets, taking syrups, or getting injections have been the most common ways to deliver drugs into the body. However, these methods often come with disadvantages such as stomach discomfort, liver damage due to metabolism, pain from injections, or the need for frequent dosing. To overcome these issues, scientists have developed a new method known as the Transdermal Drug Delivery System (TDDS).¹

The transdermal system delivers medicine directly through the skin and into the bloodstream. It usually comes in the form of a patch that is applied to the skin. This patch slowly releases a fixed amount of medicine over a period of time, ensuring that the drug level in the body remains steady. This method is painless, simple, and more convenient for patients who need regular medication. It also improves patient compliance because there's no need to remember multiple doses in a day.² Our skin, while acting as a natural barrier to protect the body from harmful substances, can also be used as a passage for drugs if the medicine is properly designed. The outer layer of the skin (called the stratum corneum) is the toughest part to cross, so special techniques like microneedles, penetration enhancers, and chemical carriers are used to help the drug pass through.¹ TDDS is not suitable for every drug, but it works very well for medicines that require slow and continuous release, such as nicotine (for quitting smoking), painkillers, hormonal therapy, or motion sickness medications.³

In this report, we will explore how the transdermal drug delivery system works, its benefits and limitations, the structure of the skin, the evolution of patch technologies, and the future potential of this system. As medical research continues to

grow, TDDS is expected to become even more advanced, offering patients a better and more comfortable way to take their medicine.³

Formulation Considerations

Formulating a Transdermal Drug Delivery System (TDDS) is a challenging task that requires detailed knowledge of skin biology, drug chemistry, and pharmaceutical technology. Unlike tablets or capsules, where the drug is released in the stomach and absorbed into the bloodstream, TDDS involves delivering the drug through the skin, which is a strong and protective barrier. For this reason, several key factors must be considered to ensure that the drug passes through the skin safely and effectively.⁵

1. Drug Properties

The first and most critical step in TDDS formulation is choosing a drug with suitable physicochemical properties. Not all drugs can be delivered through the skin. The ideal drug should have:

- A low molecular weight (usually less than 500 Daltons), so it can penetrate the skin layers.
- Balanced lipophilicity and hydrophilicity — it should dissolve in both fats and water to move through the skin's lipid layers and reach deeper tissues.
- High potency — since only small doses can be delivered through the skin, the drug must be effective at low concentrations.
- Stable nature — the drug should remain chemically stable throughout the shelf life of the patch and during skin contact.⁴

2. Role of Excipients

Excipients are non-drug ingredients that help in the delivery process. Choosing the right excipients is vital for a successful TDDS:

- Penetration Enhancers: These increase the permeability of the skin and help the drug pass



through more easily. Common enhancers include alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), and surfactants.

- **Polymers:** These form the structural base of the patch and help control the drug release. Examples include hydroxypropyl methylcellulose (HPMC), ethyl cellulose, and polyvinylpyrrolidone.
- **Adhesives:** These ensure the patch stays attached to the skin without causing irritation. They must be skin-friendly, non-reactive, and able to hold the patch in place for long periods.
- **Plasticizers:** These increase the flexibility and softness of the patch. They improve comfort and help prevent the patch from cracking or falling off.⁶

3. Type of Delivery System

There are different types of patch systems used in TDDS:

- **Reservoir System:** The drug is stored in a liquid or gel reservoir and is released through a rate-controlling membrane.
- **Matrix System:** The drug is embedded within a polymer matrix that releases the drug gradually as it contacts the skin.
- **Drug-in-Adhesive System:** The drug is directly mixed with the adhesive layer, making the patch simpler and thinner.⁹

4. Stability and Compatibility

The drug and other patch components must remain stable under different environmental conditions like heat, light, humidity, and pressure. Incompatibility between drug and excipients can lead to reduced effectiveness, patch failure, or skin reactions. Stability testing is a key step before the patch is approved for market use.⁹

5. Safety and Comfort

The patch should be safe for long-term use and must not cause any allergic reaction, rash, or skin

damage. It should also be comfortable to wear — lightweight, flexible, and non-greasy. A poor-quality patch can lead to poor patient compliance, even if the drug works well.⁸

6. Manufacturing and Quality Control

Large-scale production of transdermal patches requires consistency in drug content, patch thickness, adhesive quality, and drug release rate. Every batch must be tested for quality assurance, including drug content uniformity, adhesion strength, and skin irritation potential.

Formulating a transdermal system is a detailed process that involves choosing the right drug, selecting safe and effective excipients, and designing a patch that delivers the drug at a controlled rate. Each step must be carefully planned and tested to ensure the product is safe, effective, stable, and acceptable to patients. When done properly, transdermal systems offer a comfortable and efficient way to deliver drugs and improve treatment outcomes.⁸

Components used in TDDS:

1. Backing Layer

This is the outermost layer of the patch. It protects the patch from the external environment and provides structural support. It must be flexible, impermeable to the drug, and resistant to moisture and heat. The backing layer also prevents the drug from evaporating or leaking out of the patch.

Materials used: Polyester film, aluminum foil, polyethylene, and polyvinyl chloride.

2. Drug Reservoir / Drug Matrix

This layer contains the active drug. Depending on the type of patch, the drug may be:

- Stored in a reservoir, which holds the drug in a liquid or gel form behind a membrane, or
- Dispersed in a polymeric matrix, which releases the drug slowly when in contact with the skin.

This is the heart of the system, as it holds the actual medicine that needs to be delivered.



3. Release Liner

The release liner is a protective film that covers the adhesive layer and is removed just before applying the patch. It protects the drug and adhesive from contamination or loss before use.

Materials used: Silicone-coated paper or plastic films, which do not stick permanently to the adhesive.

4. Adhesive Layer

This layer sticks the patch to the skin and must remain in contact throughout the entire wear time. The adhesive should be non-irritating, skin-friendly, and should not interfere with drug release.

There are two types:

- Peripheral adhesive: Applied only around the edges of the patch.
- Drug-in-adhesive: The drug is mixed directly with the adhesive material.

Materials used: Acrylates, silicones, or polyisobutylenes.

5. Membrane (in reservoir systems only)

In reservoir-type patches, a semi-permeable membrane lies between the drug reservoir and the adhesive layer. It controls the rate at which the drug is released onto the skin.

This membrane must allow a steady and predictable amount of drug to pass through. Materials used: Ethylene vinyl acetate (EVA), silicone, or polyurethane membranes.

6. Penetration Enhancers (optional)

These are not visible parts of the patch but are often included in the formulation. They help the drug penetrate the outer layer of the skin (stratum corneum) more easily.

Examples: Ethanol, oleic acid, menthol, or surfactants.

Summary:

Component	Function
Backing Layer	Protects the patch from external damage
Drug Reservoir/Matrix	Holds and releases the drug
Release Liner	Covers the patch before application
Adhesive Layer	Sticks the patch to the skin
Membrane (if used)	Controls drug release rate
Penetration Enhancers	Helps drug pass through the skin barrier

Each of these components must be carefully selected based on the drug, desired release time, target condition, and patient comfort. When combined correctly, they form an efficient and reliable transdermal drug delivery system that improves therapy outcomes and enhances patient experience.¹⁶

Evaluation Parameters of Transdermal Drug Delivery System

Evaluating a Transdermal Drug Delivery System (TDDS) is an important step before it can be used by patients. Even though the patch may look small and simple, it goes through various tests to make sure it is safe, effective, comfortable, and works as expected. These tests are called evaluation parameters, and they help to check the quality, performance, and reliability of the patch.¹⁷

Below are the key evaluation parameters used in TDDS:

1. Physical Appearance

This is a basic but important check. The patch should have a smooth surface, uniform thickness, and no visible cracks, air bubbles, or drug crystals. The color, shape, and overall look of the patch should be consistent for all samples.

2. Thickness of the Patch

Uniform thickness is necessary for proper drug release. Thickness is usually measured using a micrometer screw gauge or digital thickness tester at multiple points across the patch.

3. Weight Variation

All patches should have a similar weight. Weight variation is checked by weighing several patches individually and comparing them. Large differences in weight can lead to inconsistent drug delivery.

4. Folding Endurance

This test checks the flexibility and strength of the patch. The patch is repeatedly folded at the same place until it breaks or shows cracks. A high folding endurance indicates good flexibility and durability.

1. Drug Content Uniformity

It is essential that each patch contains the same amount of drug. For this test, a patch is dissolved in a suitable solvent, and the amount of drug present is measured using techniques like UV spectroscopy or HPLC (High-Performance Liquid Chromatography).

2. Moisture Content and Moisture Uptake

This test ensures the patch is stable in different environmental conditions:

- Moisture Content tells how much water is present in the patch.
- Moisture Uptake checks how much water the patch absorbs when kept in humid conditions.

Too much moisture can affect drug stability and adhesive properties.

3. Tensile Strength

This measures the strength of the patch and its ability to withstand stretching or pulling. A patch with good tensile strength won't tear easily during handling or application.

4. Adhesive Properties

The patch must stick well to the skin without causing irritation or falling off. Adhesion tests check:

- Peel strength (how much force is needed to remove it),
- Tackiness (instant stickiness),
- And how long it can stay attached under normal conditions.

5. In-vitro Drug Release Study

This test shows how much drug is released from the patch over time. It is done using special lab equipment like Franz diffusion cells. The goal is to ensure a controlled and steady release of the drug throughout the usage period.

6. Skin Irritation Study

Before using on humans, patches are tested on animal or artificial skin models to check if they cause redness, rashes, itching, or allergic reactions. Only safe patches move forward to human use.²⁵

CONCLUSION

This article provides an valuable information regarding the transdermal drug delivery systems and its evaluation process. The foregoing shows that TDDS have great potentials, being able to use for both hydrophobic and hydrophilic active substance into promising deliverable drugs. To optimize this drug delivery system, greater understanding of the different mechanisms of biological interactions, and polymer are required. TDDS a realistic practical application as the next generation of drug delivery system.

All these evaluation parameters are necessary to confirm that the transdermal patch is safe, effective, and suitable for patients. These tests also help in maintaining the quality and consistency of the final product before it reaches the market.



REFERENCES

1. Loyd V. Allen Jr, Nicholas G. Popovich, Howard C. Ansel. Pharmaceutical dosage forms and drug delivery systems, 8th Edition., Wolter Kluwer Publishers, New Delhi, 2005 pp. 298- 299.
2. Kumar P, Sankar C, Mishra B. Delivery of macromolecules through skin. The Indian Pharmacist 2004,5(3): 7-17.
3. Kumar R, Philip A. Modified Transdermal Technologies:
Breaking the Barriers of Drug Permeation via the Skin. Trop J Pharm Res. 2007, 6(1):633-644.
4. Rizwan M, Aqil M, Talegoankar S, Azeem A, Sultana Y, Ali A. Enhanced transdermal drug delivery techniques: an extensive review on patents. Recent Pat Drug Deliv&formul. 2009, 3(2):105-24.
5. Cheston M. Berlin. Clinical report-Alternative Routes of Drug Administration-Advantages & Disadvantages (subject review). Pediatrics 1997.
6. Rizwan M, Aqil M, Talegoankar S, Azeem A, Sultana Y, Ali A. Enhanced transdermal drug delivery techniques: an extensive review on patents. Recent Pat Drug Deliv&formul. 2009, 3(2):105-24.
7. Weiner E, Victor A, Johansson ED. Plasma levels of dNorgestrel after oral administration. Contraception 1976, 14: 563-570.
8. Keith AD, Polymer matrix consideration for Transdermal Devices. Drug DevInd Pharm. 1983, 9: 605-625.
9. Karim A. Transdermal absorption: a unique opportunity for constant delivery of nitroglycerin. Drug DevInd Pharm. 1983, 9: 671.
10. Helier J, Trescony PV. Controlled drug release by polymer dissolution II, Enzyme mediated delivery device. J. Pharm. Sci. 1979, 68: 919.
11. <http://www.pharmainfo.net/reviews/transdermal-drugdelivery-technology-revisited-recent-advances>
12. <http://www.pharmainfo.net/jasmine-jose/transdermalpatches-innovative-technology>
13. Hopp SM. Developing Custom Adhesive Systems for Transdermal Drug Delivery Products. Pharmaceutical Technology 2002, 30-36.
14. <http://ezinearticles.com/?Transdermal-Drug-Delivery,-Transdermal-Patches&id=155961>
15. Hopp SM. Developing Custom Adhesive Systems for Transdermal Drug Delivery Products. Pharmaceutical Technology 2002, 30-36
16. Grossberg GT, Sadowsky C, Olin JT. Rivastigmine Transdermal System for the Treatment of Mild to Moderate Alzheimer's Disease. Int J ClinPract. 2010, 64(5): 651-660.
17. Venkatraman S, Gale R. Skin adhesives and skin adhesion. 1. Transdermal drug delivery systems. Biomaterials 1998, 19(13): 1119-36
18. Tipre ND & Vavia RP. Formulation Optimization and Stability Study of Transdermal Therapeutic System of Nicorandil. Informa Healthcare 2002, 7(3):325-332.
19. Calhoun A Darlene et al. Recent Advances in Neonatal Pharmacotherapy: Transdermal Therapy in Neonates. Ann. Pharmacother. 2006, 40 (4): 710-719.
20. <http://www.theiaforum.org/april2004.htm>
21. Sugar IP, Neumann E. Stochastic model for electric field induced membrane pores. Electroporation. Biophys. Chem. 1984, 19(3): 211. 25.



22. http://berkeley.edu/news/media/releases/2007/02/12_IRE.shtml
23. Baker W and Heller J. "Material Selection for Transdermal Delivery Systems", In *Transdermal Drug Delivery: Developmental Issues and Research Initiatives*, J.Hadgraft and R.H.Guys, Eds. Marcel Dekker, Inc., New York 1989 pp. 293-311.
24. Wiechers J. Use of chemical penetration enhancers in Transdermal drug delivery-possibilities and difficulties. *Acta pharm.* 1992 : 4: 123.
25. Yamamoto T, Katakabe k, Akiyoshi K, Kan K and Asano T. Topical application of glibenclamide lowers blood glucose levels in rats. *Diabetes res. Clin. Pract.* 1990; 8: 19-22.

HOW TO CITE: Pratik Gayke, Suvarna Bhokare , Abhay Gholwe, Sachin Ghule, Shubham Ghuge, Monika Ghuge, Transdermal drug delivery system : A journey through the skin, *Int. J. of Pharm. Sci.*, 2026, Vol 4, Issue 4, 4592-4598, <https://doi.org/10.5281/zenodo.19815645>